HOPA’s Patient Advisory Panel Helps Patients Advocate for a Pharmacist on Every Cancer Care Team
May 26th 2022Karen Fancher, PharmD, BCOP, a member of the Patient Advisory Panel at the Hematology/Oncology Pharmacy Association (HOPA), explains how her experience as a patient with cancer and an oncology pharmacy specialist informs her work on HOPA’s Patient Advisory Panel.
Watch
Daily Medication Pearl: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
May 25th 2022Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Read More